Study of Proteins in Promoting Chemotherapy Resistance in Samples From Patients With Acute Myeloid Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01419496|
Recruitment Status : Completed
First Posted : August 18, 2011
Last Update Posted : May 18, 2016
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about cancer and development of drug resistance in patients.
PURPOSE: This research trial is studying proteins that may promote chemotherapy resistance in samples from patients with acute myeloid leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: protein expression analysis Other: flow cytometry Other: laboratory biomarker analysis|
- Investigate whether changes in prosurvival signaling occur by comparing activation of the signal transducer and activator of transcription-3 (Stat3) and Stat5 pathways in paired diagnostic and relapse samples.
- Investigate changes in leukemia cell responses to extrinsic cues from the environment change, using a bone marrow stromal-cell co-culture model of chemotherapy resistance.
OUTLINE: Cryopreserved samples are analyzed for Stat3 and Stat5 expression by flow cytometry and in vitro chemotherapy sensitivity.
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Official Title:||Identifying Stat3-Dependent Chemotherapy Resistance Pathways in Relapsed AML|
|Study Start Date :||September 2011|
|Actual Primary Completion Date :||May 2016|
- Changes in Stat3 and Stat5 in paired diagnostic and relapsed AML samples
- Reduction in chemotherapy sensitivity by relapsed samples compared to diagnostic samples
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01419496
|Principal Investigator:||Michele S. Redell, MD, PhD||Texas Children's Cancer Center|